Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
A groundbreaking study published in Research (2025, DOI: 10.34133/research.0545) has elucidated the molecular mechanisms by which protein phosphatase 2A (PP2A) regulates CD8+ T cell-mediated immune ...
An international research team led by Cologne-based plant scientist Professor Dr. Bart Thomma from the Institute for Plant ...
Scientists have discovered that our specialized immune cells, called T cells, are what they eat -- their switch from functional to 'exhausted' depends on the switch from metabolizing acetate to ...
Chimeric antigen receptor-T (CAR-T) cell therapy represents a major breakthrough in cancer immunotherapy, providing remarkable clinical benefits for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results